Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

89 Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy.

Tytuł:
Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy.
Autorzy:
Yang R; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Lu M; Internal Medicine, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Ming L; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Chen Y; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Cheng K; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Zhou J; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Jiang S; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Lin Z; Ministry of Education Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection for Food Safety, College of Chemistry, Fuzhou University, Fuzhou 350116, People's Republic of China.
Chen D; Research Institute for Reproductive Health and Genetic Diseases, Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, People's Republic of China.
Źródło:
International journal of nanomedicine [Int J Nanomedicine] 2020 Nov 17; Vol. 15, pp. 9061-9074. Date of Electronic Publication: 2020 Nov 17 (Print Publication: 2020).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Auckland : DOVE Medical Press,
MeSH Terms:
Liposomes/*chemistry
Neoplastic Stem Cells/*drug effects
Radioisotopes/*chemistry
Triple Negative Breast Neoplasms/*diagnostic imaging
Triple Negative Breast Neoplasms/*drug therapy
Zirconium/*chemistry
Adult ; Aged ; Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Chitosan/chemistry ; Female ; Humans ; Hyaluronan Receptors/chemistry ; Hyaluronan Receptors/metabolism ; Liposomes/pharmacokinetics ; Mice, Nude ; Middle Aged ; Molecular Docking Simulation ; Molecular Targeted Therapy/methods ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Positron-Emission Tomography/methods ; Tissue Distribution ; Triple Negative Breast Neoplasms/pathology ; Xanthones/pharmacokinetics ; Xenograft Model Antitumor Assays
References:
ISRN Pharm. 2012;2012:636743. (PMID: 22500244)
Oxid Med Cell Longev. 2019 Feb 14;2019:9078209. (PMID: 30906504)
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. (PMID: 12629218)
Cell Cycle. 2010 Jul 15;9(14):2878-87. (PMID: 20581442)
ACS Nano. 2015 Jun 23;9(6):5725-40. (PMID: 26004286)
Cureus. 2019 Jun 21;11(6):e4963. (PMID: 31453035)
Oncol Lett. 2017 Nov;14(5):5890-5898. (PMID: 29113223)
Polymers (Basel). 2018 Apr 23;10(4):. (PMID: 30966497)
Med Oncol. 2015 Jan;32(1):275. (PMID: 25429827)
J Microsc Ultrastruct. 2017 Apr-Jun;5(2):59-69. (PMID: 30023238)
Anticancer Agents Med Chem. 2012 Oct 1;12(8):994-1000. (PMID: 22339063)
Surg Clin North Am. 2018 Aug;98(4):773-785. (PMID: 30005773)
Drug Discov Today. 2017 Apr;22(4):665-680. (PMID: 28017836)
Carbohydr Polym. 2017 May 1;163:34-42. (PMID: 28267516)
Int J Nanomedicine. 2018 Oct 04;13:6049-6058. (PMID: 30323592)
Int J Biochem Cell Biol. 2016 Dec;81(Pt A):166-173. (PMID: 27640754)
Adv Mater. 2018 Mar;30(13):e1704934. (PMID: 29430735)
Colloids Surf B Biointerfaces. 2017 Oct 1;158:356-362. (PMID: 28719856)
Molecules. 2013 Jun 03;18(6):6469-90. (PMID: 23736785)
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110. (PMID: 25510809)
J Mol Med (Berl). 2016 May;94(5):509-22. (PMID: 26689709)
Nat Med. 2017 Oct 6;23(10):1124-1134. (PMID: 28985214)
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. (PMID: 27184417)
Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):77-91. (PMID: 28891438)
Nanomedicine (Lond). 2016 Dec;11(24):3261-3282. (PMID: 27854161)
J Hematol Oncol. 2018 May 10;11(1):64. (PMID: 29747682)
ACS Nano. 2018 Aug 28;12(8):8646-8661. (PMID: 30081622)
Breast. 2018 Jun;39:131-138. (PMID: 29679849)
Life Sci. 2017 Feb 1;170:56-63. (PMID: 27919820)
Contributed Indexing:
Keywords: CD44; CS; PET; molecular docking; molecular dynamics simulation; radionuclide
Substance Nomenclature:
0 (Antineoplastic Agents)
0 (CD44 protein, human)
0 (Hyaluronan Receptors)
0 (Liposomes)
0 (Radioisotopes)
0 (Xanthones)
8N585K83U2 (gambogic acid)
9012-76-4 (Chitosan)
C6V6S92N3C (Zirconium)
NTM296JU95 (Zirconium-89)
Entry Date(s):
Date Created: 20201126 Date Completed: 20210108 Latest Revision: 20220418
Update Code:
20240105
PubMed Central ID:
PMC7680801
DOI:
10.2147/IJN.S262786
PMID:
33239874
Czasopismo naukowe
Purpose: Therapy for triple-negative breast cancer (TNBC) is a global problem due to lack of specific targets for treatment selection. Cancer stem cells (CSCs) are responsible for tumor formation and recurrence but also offer a promising target for TNBC-targeted therapy. Here, zirconium-89 ( 89 Zr)-labelled multifunctional liposomes (MLPs) surface-decorated with chitosan (CS) were fabricated to specifically target and trace cluster of differentiation 44 + (CD44 + ) TNBC CSCs specifically.
Patients and Methods: The biological basis of CS targeting CD44 for cancer therapy was investigated by detecting the expression of CD44 in TNBC CSCs and TNBC tissues. Molecular docking and dynamics simulations were performed to investigate the molecular basis of CS targeting CD44 for cancer therapy. Gambogic acid (GA)-loaded, 89 Zr@CS-MLPs ( 89 Zr-CS-GA-MLPs) were prepared, and their uptake and biodistribution were observed. The anti-tumor efficacy of 89 Zr@CS-GA-MLPs was investigated in vivo.
Results: CD44 is overexpressed in TNBC CSCs and tissues. Molecular docking and dynamics simulations showed that CS could be stably docked into the active site of CD44 in a reasonable conformation. Furthermore, 89 Zr@CS-GA-MLPs were able to bind specifically to CD44 + TNBC stem-like cells and accumulated in tumors of xenograft-bearing mice with excellent radiochemical stability. 89 Zr@CS-GA-MLPs loaded with GA showed remarkable anti-tumor efficacy in vivo.
Conclusion: The GA-loaded, 89 Zr-labelled, CS-decorated MLPs developed in this study represent a novel strategy for TNBC imaging and therapy.
Competing Interests: The authors report no conflicts of interest in this work.
(© 2020 Yang et al.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies